Table 2.
CVD Risk Scores: Median Follow‐Up, Events, Discrimination, and Calibration
| N | Median follow‐up, y (quartile 1–quartile 3) | Events | Median risk score (quartile 1–quartile 3) | Discrimination c‐statistic (95% CI) | Calibration χ 2 | Calibration P value | |
|---|---|---|---|---|---|---|---|
| ACC/AHA | |||||||
| Women | 810 | 6.40 (2.96–10.0) | 31 | 0.019 (0.009–0.046) | 0.780 (0.694–0.866) | 4.22 | 0.1210 |
| Men | 5926 | 5.39 (2.48–10.0) | 248 | 0.048 (0.025–0.087) | 0.706 (0.672–0.7404) | 10.55 | 0.005 |
| FHS CHD | |||||||
| Women | 1261 | 6.32 (2.85–10.0) | 15 | 0.007 (0.003–0.014) | 0.901 (0.846–0.956) | 3.43 | 0.1800 |
| Men | 8133 | 5.16 (2.34–10.0) | 143 | 0.031 (0.018–0.054) | 0.718 (0.673–0.763) | 24.12 | <0.0001 |
| FHS CVD | |||||||
| Women | 1261 | 6.24 (2.81–10.0) | 36 | 0.013 (0.008–0.026) | 0.784 (0.712–0.857) | 13.52 | 0.0012 |
| Men | 8133 | 5.09 (2.30–10.0) | 267 | 0.037 (0.021–0.065) | 0.723 (0.690–0.756) | 6.37 | 0.0413 |
ACC/AHA indicates American College of Cardiology/American Heart Association; CVD, cardiovascular disease; FHS CHD, Framingham Heart Study hard coronary heart disease (function); and FHS CVD, Framingham Heart Study hard caddiovascular disease (function).